Trillium Therapeutics Inc.
Formerly Stem Cell Therapeutics Corp., Neurogenesis Biotech Corp.
Funding rounds
1 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Dec 2017 | $20 M | No. 1 | $10 to $50 million | equity | SEC |
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Trillium Therapeutics Inc. chose not to state its revenue in its newest notice of a funding round (Dec 2017).
SEC Form D · Dec 2017
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Dec 2017
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
No investor of Trillium Therapeutics Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Eric Sievers | Executive officer | Dec 2017 |
| James Parsons | Executive officer | Dec 2017 |
| Niclas Stiernholm | Executive officer | Dec 2017 |
| Penka Petrova | Executive officer | Dec 2017 |
| Robert Uger | Executive officer | Dec 2017 |
| Calvin Stiller | Director | Dec 2017 |
| Helen Tayton-Martin | Director | Dec 2017 |
| Henry Frieson | Director | Dec 2017 |
| Luke Beshar | Director | Dec 2017 |
| Michael Moore | Director | Dec 2017 |
| Niclas Stiernholm | Director | Dec 2017 |
| Robert Kirkman | Director | Dec 2017 |
| Thomas Reynolds | Director | Dec 2017 |